Moderna shares jump 4.4% ahead of Phase‑3 melanoma data and BofA price‑target lift
Moderna (MRNA) stock rose about 4.4% on Oct. 19 as investors positioned for the full Phase‑3 INTerpath‑001 melanoma trial results to be presented at the ESMO Congress on Oct. 24. Bank of America raised its price target to $220 from $200 while keeping a Neutral rating. The move follows a near‑10% pull‑back the prior Friday and the company’s recent addition to the Nasdaq‑100 index.
Why it matters
The upcoming data release is a binary catalyst that could materially affect Moderna’s valuation and the price of its shares, as noted by Bank of America’s target increase. Analysts such as Jefferies see peak melanoma sales potential above $3 billion, indicating a sizable upside if the trial meets expectations.
Key facts
- 1Moderna shares rose 4.4% to $227.50 in morning trading. investing.com
- 2Moderna shares rose 4.4% to $227.61 according to Benzinga data. benzinga.com
- 3Bank of America raised its price target on Moderna to $220 from $200, keeping a Neutral rating. investing.com
- 4The Phase‑3 INTerpath‑001 trial evaluated intismeran autogene plus Keytruda versus Keytruda alone in 1,137 patients with resected stage IIB‑IV melanoma. benzinga.com
- 5Full trial results are scheduled for presentation at the ESMO Congress on Oct. 24, 2026. investing.com
- 6Moderna’s stock fell nearly 10% on Friday, its biggest drop since the prior week. benzinga.com
Open questions
- Two sources report slightly different closing prices ($227.50 vs $227.61) for the same trading day.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.